Wire · opportunities
FDA advisory panel votes to place popular peptide TB-500 on compounding list
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
An FDA advisory panel voted 8-6 to place TB-500, a popular peptide, on the pharmacy compounding list, allowing broader production outside traditional pharmaceutical manufacturing. The FDA is not bound by the recommendation and will make the final decision.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 23 Jul 2026 and 24 Jul 2026.
◆ ◆ The Wire takeaway
If you supply peptide raw materials or fill-finish services to compounding pharmacies, you've just gained access to a major new customer category overnight—once the FDA formalises this decision. The panel vote signals the regulator is moving toward allowing decentralised peptide production, which means pharmacy-scale manufacturing now competes with your current customer base.
◆ Coverage
2 sources · first reported 23 Jul 2026 · latest 24 Jul 2026
◆ Related on Wire
◆ Topics